Since reduced expression or deleterious mutations of HVEM was found to promote lymphomagenesis and tumor development in patients with FL and DLBCL, this molecule has been proposed as a possible therapeutic target [82]. Here, TNFRSF14 is linked to diffuse large B-cell lymphoma.